Generated by AI
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver diseases and viral infections. The company’s current programs target chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, and coronavirus-related infections, using small-molecule and oligonucleotide approaches. Its pipeline includes investigational candidates designed to address unmet medical needs in these disease areas, with emphasis on antiviral activity and liver-disease biology. Aligos Therapeutics also works through research collaborations and licensing arrangements that support development of selected programs. Based in South San Francisco, California, Aligos Therapeutics operates within the biotechnology sector as a drug-development company centered on advancing therapies from discovery through clinical evaluation.
WebsiteOne Corporate Drive
South San Francisco, CA, 94080
United States
The latest articles about ALGS.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2026. “This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late
Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.
Summary of Jul 8's posts. Generated by AI.
Summary of Jul 6's posts. Generated by AI.
Summary of Jan 7's posts. Generated by AI.
Summary of Apr 16's posts. Generated by AI.
Investors talking about ALGS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.